Extended Data Fig. 5: Selective inhibition of oncogenic signaling driven by various KRAS mutants.
From: Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Extracts from cell lines treated with the KRAS inhibitor were subjected to RBD pull-down and immunoblotting to determine the effect on KRAS and ERK signaling activation. WT: wild-type, UAWT: upstream activated wild-type. Co-occurring alterations in select other genes are shown. The data in Fig. 4a are densitometric quantifications of the immunoblots shown here.